Skip to main content

Find Clinical Trials

Home
Conditions
Thrombotic Microangiopathies

Clinical trial condition

Thrombotic Microangiopathies

Explore clinical trials studying Thrombotic Microangiopathies. Study availability and eligibility vary by location and protocol.

395 public trials 101 recruiting studies

Refine in advanced search Browse all conditions

Thrombotic Microangiopathies trial results

Completed

Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS

NCT00844844

Conditions: Anemia, Anemia, Hemolytic, Atypical Hemolytic Uremic Syndrome, +14 more
Locations: Atlanta, Georgia, United States

Fort Wayne, Indiana, United States

New York, United States

New York, United States

View all 17 locations

View Trial Details

Completed

An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome

NCT01193348

Conditions: Anemia, Anemia, Hemolytic, Atypical Hemolytic Uremic Syndrome, +15 more
Locations: Atlanta, Georgia, United States

Hackensack, New Jersey, United States

Corpus Christi, Texas, United States

Spokane, Washington, United States

View all 17 locations

View Trial Details

Completed

NATURAL KILLER CELLS IN IMMUNOLOGIC THROMBOCYTOPENIC PURpura of Adults

NCT01172015

Conditions: Autoimmune Diseases, Blood Coagulation Disorders, Blood Platelet Disorders, +16 more
Locations: APHM Marseille, France

View Trial Details

Completed

A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

NCT01098487

Conditions: Blood Coagulation Disorders, Blood Platelet Disorders, Cytopenia, +13 more
Locations: GSK Investigational Site New York, United States

GSK Investigational Site Hradec Králové, Czechia

GSK Investigational Site Olomouc, Czechia

GSK Investigational Site Prague, Czechia

View all 34 locations

View Trial Details

Completed

Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.

NCT01520909

Conditions: Autoimmune Diseases, Blood Coagulation Disorders, Blood Platelet Disorders, +16 more
Locations: GSK Investigational Site Los Angeles, California, United States

GSK Investigational Site St. Petersburg, Florida, United States

GSK Investigational Site Brooklyn, New York, United States

GSK Investigational Site Salt Lake City, Utah, United States

View all 51 locations

View Trial Details

Completed

A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.

NCT00475423

Conditions: Autoimmune Diseases, Blood Coagulation Disorders, Blood Platelet Disorders, +16 more
Locations: Adelaide, New South Wales, Australia

Gosford, New South Wales, Australia

Randwick, New South Wales, Australia

Sydney, New South Wales, Australia

View Trial Details

Completed

A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

NCT00770562

Conditions: Autoimmune Diseases, Blood Coagulation Disorders, Blood Platelet Disorders, +16 more
Locations: Bari, Italy

Bologna, Italy

Brescia, Italy

Cagliari, Italy

View all 22 locations

View Trial Details

Completed

Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura

NCT00486421

Conditions: Autoimmune Diseases, Blood Coagulation Disorders, Blood Platelet Disorders, +16 more
Locations: Mayo Clinic Rochester, Minnesota, United States

View Trial Details

Completed

Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults

NCT00426270

Conditions: Autoimmune Diseases, Blood Coagulation Disorders, Blood Platelet Disorders, +16 more
Locations: Contact Octapharma for information Vienna, Austria

View Trial Details

Completed

Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects

NCT00515203

Conditions: Autoimmune Diseases, Blood Coagulation Disorders, Blood Platelet Disorders, +18 more
Locations: Not specified

View Trial Details